Exscientia Reports Loss of $0.38 per Share Despite Revenue of $7.1M
June 19, 2023
🌥️Trending News
EXSCIENTIA ($NASDAQ:EXAI): The company reported a loss of $0.38 per share under Generally Accepted Accounting Principles (GAAP), despite its revenue reaching $7.1 million. This increase was largely driven by the company’s growing portfolio of drug discovery programs, as well as its expanding customer base. The company attributed this to increased spending on research and development, as well as continuing investments in artificial intelligence technology. Looking ahead, the company expects these expenses to continue to rise in order to remain competitive in the rapidly evolving AI drug discovery market.
Earnings
In the latest earnings report of FY2022 Q4 ending December 31 2022, EXSCIENTIA PLC reported total revenue of 8.2M USD and net income loss of 47.2M USD. Compared to the previous year, total revenue increased by 46.4%. Over the past three years, EXSCIENTIA PLC’s total revenue has grown from 5.82M USD to 8.2M USD.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Exscientia Plc. More…
| Total Revenues | Net Income | Net Margin |
| 26.01 | -140.88 | -579.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Exscientia Plc. More…
| Operations | Investing | Financing |
| -88.26 | -281.76 | -2.06 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Exscientia Plc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 603.29 | 155.57 | 3.62 |
Key Ratios Snapshot
Some of the financial key ratios for Exscientia Plc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 44.1% | – | -629.9% |
| FCF Margin | ROE | ROA |
| -458.1% | -22.1% | -17.0% |
Share Price
Despite this, EXSCIENTIA stock opened at $7.3 and closed at $8.1, representing a 6.0% increase from its previous closing price of $7.6. The company’s losses were largely attributed to higher costs associated with research and development. Despite this, analysts are optimistic that the company can recover in the coming quarters, due to its strong focus on AI drug discovery. Live Quote…
Analysis
GoodWhale conducted an analysis of the financials of EXSCIENTIA PLC. The Star Chart showed that EXSCIENTIA PLC has an intermediate health score of 6/10, with strong assets and growth, but weak dividend and profitability. We concluded that EXSCIENTIA PLC is a ‘rhino’ type of company, that has achieved moderate revenue or earnings growth. This analysis could be interesting to investors who are seeking moderate growth. EXSCIENTIA PLC’s cashflows and debt may indicate they have the ability to pay off debt and fund future operations. Therefore, this could be an attractive investment for those investors who are looking for a balance between risk and return. More…
Peers
It is one of the leading artificial intelligence-driven drug discovery companies in the world and competes with IDEAYA Biosciences Inc, Navidea Biopharmaceuticals Inc, and Cogent Biosciences Inc. These companies are each engaged in research and development of drug discovery and development, using various technologies to bring new treatments to market.
– IDEAYA Biosciences Inc ($NASDAQ:IDYA)
IDEAYA Biosciences Inc is a biotechnology company that discovers and develops small molecule therapeutics for cancer and other genetically defined diseases. The company has a market cap of 830.92M as of 2023, making it one of the larger biotechnology companies in the industry. The company’s Return on Equity (ROE) is currently -10.66%, which suggests that there is an absence of profitability in the company’s operations. This could be a result of a lack of sales, mismanagement, or a combination of both. Nevertheless, the company has managed to remain competitive and maintain its large market cap despite its current negative ROE.
– Navidea Biopharmaceuticals Inc ($NYSEAM:NAVB)
Navidea Biopharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company has a market cap of 8.41M as of 2023, indicating its potential to grow in the near future. In addition, its Return on Equity (ROE) is 186.19%, implying that it is generating a considerable amount of income and effectively managing its resources. Navidea’s strong financial performance is indicative of its successful business strategy and its commitment to providing innovative diagnostic and therapeutic solutions to patients worldwide.
– Cogent Biosciences Inc ($NASDAQ:COGT)
Cogent Biosciences Inc is a biopharmaceutical company that develops and commercializes novel therapies for the treatment of a wide range of diseases. As of 2023, the company has a market cap of 873.67M and a Return on Equity of -26.61%. Cogent Biosciences’ market cap is indicative of its strong financial position, as it is able to generate a healthy amount of capital from its operations and investments. However, its negative Return on Equity indicates that the company has yet to generate a significant return on its investments.
Summary
Exscientia PLC is a publicly traded company that has recently released its quarterly financial report for the period ending March 31st. The report showed a GAAP earnings per share (EPS) of -$0.38 and revenue of $7.1 million. Despite this, the stock price for Exscientia was up on the day of the announcement, indicating that investors were relatively undeterred by the negative EPS number. Despite this, Exscientia’s unique focus on AI-driven drug discovery and development could be a competitive advantage in the long-term, making the company an attractive investment for those looking for potential growth over the next few years.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
